# Cell Cycle Regulation > Cell cycle regulation in MBBS Biochemistry: cyclins and CDKs, G1/S restriction point, p53 and Rb, checkpoints and cancer therapy links. - Canonical URL: https://prepelephant.com/topics/mbbs/biochemistry/cell-cycle-regulation - Exam / course: MBBS · Subject: Biochemistry - Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team - First published: 2026-10-02 - Last updated: 2026-10-02 - How to cite: "Cell Cycle Regulation", PrepElephant, https://prepelephant.com/topics/mbbs/biochemistry/cell-cycle-regulation ## Direct answer Cyclin-dependent kinases drive the cycle forward while checkpoints pause it: cyclin D partners CDK4 and CDK6 early in G1, cyclin E-CDK2 crosses the restriction point committing to DNA synthesis, cyclin A-CDK2 runs S phase, and cyclin B-CDK1 (maturation promoting factor) triggers mitosis. The guardrails are tumour suppressors — hypophosphorylated Rb binds E2F until cyclin D-CDK4 phosphorylation releases it, and p53 halts the cycle through p21 after DNA damage, either repairing or apoptosis-directing the cell. The spindle assembly checkpoint at metaphase holds anaphase until every kinetochore attaches; loss of these controls, most famously p53 mutation in over half of human cancers and Rb pathway disruption, converts regulation into oncogenesis. ## What you must remember - **Phase durations for a cycling cell (classic 24-hour fibroblast):** G1 about 11 hours, S roughly 8, G2 about 4, M roughly 1; G0 is the quiescent exit taken by hepatocytes and neurons, reversible for liver but not for most neurons. - **Restriction point (G1/S):** the growth-factor-dependent commitment gate; beyond it, the cycle runs even if mitogens are withdrawn, and it is the step most often deranged in cancer by cyclin D amplification, CDK4 overexpression or Rb loss. - **Rb logic:** hypophosphorylated Rb sequesters E2F; sequential phosphorylation by cyclin D-CDK4/6 then cyclin E-CDK2 frees E2F to transcribe S-phase genes; human DNA tumour viruses (HPV E7, SV40 large T) bind and neutralise Rb. - **p53 as guardian of the genome:** DNA damage activates ATM/ATR kinases, stabilising p53, which induces p21 (CDK inhibition), GADD45, DNA-repair genes and Bax; germline p53 mutation causes Li-Fraumeni syndrome with breast, sarcoma, adrenal and brain tumours. - **Spindle checkpoint:** MAD and BUB proteins sense unattached kinetochores and block the anaphase-promoting complex/cyclosome until alignment; its failure yields aneuploidy, and taxanes and vinca alkaloids exploit spindle dynamics to arrest mitosis lethally. - **CDK inhibitors:** Cip/Kip family (p21, p27, p57) and INK4 family (p16, specific for CDK4/6); p16 loss and cyclin D1 overexpression in parathyroid adenoma and mantle-cell lymphoma t(11;14) are standard oncology links. - **Proliferation markers:** Ki-67 stains all active phases (G1 through M), prognostically used in breast and neuroendocrine tumours; BrdU incorporation labels S phase. ## How to work through a checkpoint-failure case A 35-year-old woman with early bilateral breast cancer, a brother with osteosarcoma and an aunt with leukaemia suggests Li-Fraumeni syndrome. Reason along the checkpoint: germline TP53 mutation removes the DNA-damage brake, so radiation-damaged cells neither arrest nor apoptose but accumulate mutations — explaining both the tumour spectrum and the caution with radiation therapy in such patients. The molecular logic parallels the Rb story: two-hit loss in retinoblastoma gave Knudson the model, and HPV carcinogenesis compresses the teaching into two oncoproteins, E7 neutralising Rb and E6 targeting p53 for ubiquitin-mediated destruction, which is why cervical cancer is effectively a virally engineered checkpoint-double-failure. Therapy follows the machinery: CDK4/6 inhibitors (palbociclib) restore checkpoint pressure in hormone-receptor-positive breast cancer by blocking the cyclin D-CDK4/6 phosphorylation of Rb, holding cells in G1 — but only works when Rb itself is intact, a pharmacological proof of the pathway's logic. ## Where students slip Students credit cyclins with kinase activity; the cyclin is the regulatory partner whose binding and phosphorylation activate the CDK, and cyclin levels oscillate while CDK levels stay flat — the oscillator is protein degradation (ubiquitin-mediated) at each transition. Second, the restriction point is G1/S, not G2/M; confusing them muddles which tumour suppressors police which gate. Third, p53 induces p21, it does not directly inhibit CDKs itself — a one-mark distinction repeatedly tested. Finally, maturation promoting factor equals cyclin B-CDK1, historically discovered as "M-phase promoting factor" in frog eggs; the older name appears in Indian question papers as a deliberate synonym trap. ## Frequently asked questions ### Which cyclin-CDK complex commits the cell at the restriction point? Cyclin E-CDK2 phosphorylates Rb decisively, releasing E2F to launch S phase after the earlier cyclin D-CDK4/6 priming phosphorylations. ### How does Rb restrain cell proliferation? In its hypophosphorylated state it binds E2F transcription factors; phosphorylation by cyclin D-CDK4/6 releases E2F to transcribe the S-phase programme. ### What is p53's role after DNA damage? Stabilised through ATM-ATR signalling, it induces p21 to arrest the cycle at G1/S, promotes DNA repair, and diverts irreparable cells to apoptosis through Bax. ### Which proteins operate the spindle assembly checkpoint? MAD and BUB family proteins at unattached kinetochores inhibit the anaphase-promoting complex, delaying sister-chromatid separation until all chromosomes align. ### Which marker estimates the growth fraction of a tumour? Ki-67 immunostaining, which marks cells in all active phases of the cycle but not quiescent G0 cells.